Design Therapeutics, Inc. DSGN

DSGN Company Overview

Design Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapies to treat serious diseases caused by nucleotide repeat expansions in the genome. The company operates within the biotechnology and pharmaceutical research and development industries, with a primary emphasis on genetic and neurological disorders that currently lack effective disease-modifying treatments.

The company’s core value proposition is its proprietary GeneTAC™ (Gene Targeting Chimera) platform, which is designed to selectively target and modulate the underlying genetic drivers of repeat expansion disorders. Design Therapeutics was founded in 2017 and became a publicly traded company in 2021. Since inception, it has evolved from a platform-focused discovery organization into a clinical-stage company advancing multiple therapeutic candidates, particularly in neuromuscular and neurodegenerative diseases.